AKBA
Akebia Therapeutics, Inc.
0.96
USD
This page is just a preview of the data found in TrendSpider’s full version
Akebia Therapeutics, Inc. stock is up 13.33% since 30 days ago. The next earnings date is Mar 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 70% of the previous 9 November’s closed higher than October. 100% of analysts rate it a buy.
Akebia Therapeutics, Inc. focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients on dialysis.
